Category : NationalPublished on: September 02 2022
Share on facebook
India gets its first cervical cancer vaccine, Quadrivalent Human Papillomavirus vaccine (qHPV) today i.e. on 1 September.
The most awaited vaccine has been launched by the Union Minister of State (Independent Charge) Science & Technology Jitendra Singh at IIC Delhi.
The Drugs Controller General of India (DCGI) had on 12 July granted market authorisation to Serum Institute of India (SII) to manufacture an indigenously-developed vaccine against cervical cancer.
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
The revolutionary step for the Indian demography will now help prevent cases of cervical cancer.
The qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
When cancer starts in the cervix, it is called cervical cancer.It occurs most often in women over age 30. Long-lasting infection with certain types of human papillomavirus (HPV) is the main cause of cervical cancer. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.